Biotin

Biotin

SCHEMBL3142794

NCCc1ccc(N)cc1.O=C(O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@@H]21

nearest known ligand 0.71

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 5/20 0.71
▸ MEN1 O00255 1/20 0.71
▸ ABL1 P00519 1/20 0.71
▸ LMNA P02545 1/20 0.71
▸ PKM P14618 1/20 0.71
▸ IDE P14735 1/20 0.71
▸ MAPK1 P28482 1/20 0.71
▸ KMT2A Q03164 1/20 0.71
▸ RIN1 Q13671 1/20 0.71
▸ L3MBTL1 Q9Y468 1/20 0.71
▸ CA12 O43570 12/20 0.57
▸ CA1 P00915 12/20 0.57
▸ CA2 P00918 12/20 0.57
▸ CA9 Q16790 12/20 0.57
▸ HLCS P50747 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Biotin SCHEMBL7749208 0.93 TDP1 (0.69) TDP1MEN1ABL1LMNAPKM
Biotin SCHEMBL1757916 0.93 TDP1 (0.69) TDP1MEN1ABL1LMNAPKM
Biotin SCHEMBL438197 0.87 TDP1 (0.74) TDP1MEN1ABL1LMNAPKM
Biotin SCHEMBL453833 0.87 TDP1 (0.90) TDP1MEN1ABL1LMNAPKM
Biotin SCHEMBL1269621 0.86 TDP1 (0.72) TDP1MEN1ABL1LMNAPKM
Biotin SCHEMBL446893 0.86 TDP1 (0.79) TDP1MEN1ABL1LMNAPKM
Biotin SCHEMBL6865574 0.85 TDP1 (0.87) TDP1MEN1ABL1LMNAPKM
Biotin SCHEMBL2057282 0.85 TDP1 (0.87) TDP1MEN1ABL1LMNAPKM
Biotin SCHEMBL2484400 0.84 TDP1 (0.69) TDP1MEN1ABL1LMNAPKM
Biotin SCHEMBL739967 0.84 TDP1 (0.85) TDP1MEN1ABL1LMNAPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100081629-A1 LOW MOLECULAR WEIGHT HEPARINS INCLUDING AT LEAST ONE COVALENT BOND WITH BIOTIN OR A BIOTIN DERIVATIVE, METHOD FOR MAKING SAME AND USE THEREOF SANOFI-AVENTIS (FR) 2010-04-01 — — US disclosed
US-20100075922-A1 HEPARINS INCLUDING AT LEAST ONE COVALENT BOND WITH BIOTIN OR A BIOTIN DERIVATIVE, METHOD FOR PREPARING SAME AND USE THEREOF SANOFI-AVENTIS (FR) 2010-03-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075922-A1 HEPARINS INCLUDING AT LEAST ONE COVALENT BOND WITH BIOTIN OR A BIOTIN DERIVATIVE, METHOD FOR PREPARING SAME AND USE THEREOF BTD, HBB, HLCS TDP1 4647/4885MEN1 1640/4885ABL1 4284/4885
US-20100081629-A1 LOW MOLECULAR WEIGHT HEPARINS INCLUDING AT LEAST ONE COVALENT BOND WITH BIOTIN OR A BIOTIN DERIVATIVE, METHOD FOR MAKING SAME AND USE THEREOF BTD, CD44, HLCS TDP1 4710/4885MEN1 2181/4885ABL1 4312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback